
Job Title: Senior Director to Executive Director, Chemistry
Reports To: VP, Head of Discovery Unit 3
Location: Shanghai, China
About Us:
Structure Therapeutics develops life‐changing medicines for patients using advanced structure‐based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions.
Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company completed an initial public offering (IPO) in February 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location.
This position will play a key role in advancing the research pipeline and drug discovery projects. Anchored in Discovery Unit, the successful candidate will be responsible for designing, overseeing and interpreting in vivo studies in obesity, metabolic disease and related disease areas. The position will be an essential part of an interdisciplinary team, collaborating closely with cross-functional team members and contributing to project success.
Job Responsibilities:
Scientific and Program Leadership
Team and Organizational Leadership
Externalization and Partner Management
Cross-Functional Collaboration
Operational Excellence
Qualifications:

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.